BCR and lymphoma: BCR signaling is constitutively active in these B-cell malignancies through both ligand-dependent (triggered by antigens present in the lymphoma-associated tumor microenvironment; TME) and independent mechanisms (autonomous BCR stimulation by its epitope) leading to the activation of oncogenic NF-kB and other targeted survival signaling [2,3,4].